02 September 2019
Visiongain has launched a new pharma report Top Pre-Filled Injection Device Manufacturers 2019-2029: Profiles, R&D and Revenue Forecasting for Leading Syringe, Injector and Component Producers and Contract Filling Services.
Pre-filled syringes provide users with a number of advantages over other drug delivery systems. These include simplified storage and disposal, shorter preparation and administration time and reduced risk of medication errors. For drug manufacturers, there are also numerous advantages to pre-filled syringes. Filling syringes rather than vials cuts overfill rates, reducing wastage, and also eliminates material costs as there is no need for vials as well as syringes.
The lead analyst of the report commented "Most companies have invested in new manufacturing facilities or sales offices in emerging markets, to take advantage of lower cost manufacturing, as well as in order to appeal to emerging market drug developers. A particular target group among these companies are biosimilar developers looking to bring their drugs to developed markets. Companies have also invested in products suitable for administration of these biosimilars, as well as novel biologics. These include dual-chamber syringes and cartridges, lyophilisation and reconstitution tools, sensitive syringe coatings and polymer syringes."
Leading companies featured in the report include Aptar Stelmi, Becton, Dickinson, & Co (BD), Bespak Injectables, Boehringer Ingelheim, Catalent, Dätwyler Holding, Gerresheimer, Haselmeier, Laboratorios Farmacéuticos ROVI and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.
25 November 2022
Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.
25 November 2022
The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.
23 November 2022
The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.